問卷

TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (非在職)

Division of Nephrology

Division of Nephrology

更新時間:2023-09-19

彭渝森
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

43Cases

2021-11-01 - 2026-02-28

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2026-04-04

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-02-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-01-05 - 2029-11-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-01 - 2025-10-12

Phase III

Active
ARTEMIS: RAvulizumab to PRotect PaTients With Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
  • Condition/Disease

    PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE)

  • Test Drug

    Ravulizumab

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2024-03-15 - 2031-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
  • Condition/Disease

    Immunoglobulin A Nephropathy (IgAN)

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2021-09-21 - 2026-06-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-09-30 - 2026-06-30

Phase II

Active
A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease
  • Condition/Disease

    chronic kidney disease

  • Test Drug

    tablets

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure
  • Condition/Disease

    Chronic Kidney Disease and Hypertension

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
11Sites

Not yet recruiting5Sites

Recruiting6Sites

2023-12-28 - 2027-02-28

Phase III

A Phase III, Randomized, Investigator-Blinded, Active-Controlled Study of Efficacy and Safety of Efepoetin Alfa for Treatment of Anemia in Patients with Chronic Kidney Disease on Dialysis
  • Condition/Disease

    Chronic Kidney Disease on Dialysis

  • Test Drug

    Efepoetin alfa (GX-E4)

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5